Skip to main
MD
MD logo

MEDNAX (MD) Stock Forecast & Price Target

MEDNAX (MD) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Pediatrix Medical Group Inc. has demonstrated robust performance, with a reported 6.2% same-store growth in the first quarter of 2025, continuing the positive momentum from the second half of 2024, primarily driven by pricing strength. Additionally, improvements in margins and cash flow are anticipated as a result of recent portfolio restructurings and a transition to revenue cycle management. Furthermore, the company has revised its adjusted EPS estimates for 2025 and 2026 upward, increasing from $1.54 to $1.72 and from $1.80 to $1.84, indicating a favorable outlook on profitability moving forward.

Bears say

Pediatrix Medical Group's stock faces a negative outlook due to its business model being heavily reliant on U.S. birth rates, which have been trending downward, leading to expected ongoing headwinds. Additionally, the neonatal segment of the company exhibits limited organic growth potential and struggles with expansion into new specialty areas, potentially affecting consistent revenue growth and profit margins. Lastly, internal compensation structures may create friction among physicians, complicating recruitment efforts, while external factors such as regulatory changes and reimbursement rate shifts may further jeopardize revenue stability.

MEDNAX (MD) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MEDNAX and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MEDNAX (MD) Forecast

Analysts have given MEDNAX (MD) a Hold based on their latest research and market trends.

According to 6 analysts, MEDNAX (MD) has a Hold consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MEDNAX (MD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.